KYORIN PharmaceuticalKYORIN Pharmaceutical Co., Ltd.4569東証プライム医薬品FY ending Mar 2026, consolidated, J-GAAP

KYORIN Pharmaceutical FY ending Mar 2020 results

KYORIN Pharmaceutical brought in ¥110B in revenue.

Out of every ¥100 of sales, about ¥7 is left as operating profit.

Where the money goes

For every ¥100 KYORIN Pharmaceutical sells, how much goes where, and how much is kept.

FY ending Mar 2020

Margin funnel (derived from reported values)Gross margin 51.9% → Operating margin 6.8% → Net margin 5.6%

Show source documents (3)

EDINET (FSA Japan)
有価証券報告書－第66期(2023/04/01－2024/03/31)
ID S100TQ0U2024-06-24Open
EDINET (FSA Japan)
有価証券報告書－第64期(令和3年4月1日－令和4年3月31日)
ID S100OCVJ2022-06-24Open
EDINET (FSA Japan)
有価証券報告書－第63期(令和2年4月1日－令和3年3月31日)
ID S100LKCY2021-06-21Open

Extracted from XBRL: 45 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.